Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GILDA M DE LA CALLE

Allopathic & Osteopathic Physicians General Practice

NPI
1174622682
CMS profile
53553
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,008.58

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,008.58 94

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GILDA M DE LA CALLE

NPI 1174622682 · CMS profile ID 53553

Allopathic & Osteopathic Physicians / General Practice

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174622682?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GILDA M DE LA CALLE, NPI 1174622682, CMS profile ID 53553. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174622682?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GILDA M DE LA CALLE, NPI 1174622682, CMS profile ID 53553. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174622682?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GILDA M DE LA CALLE, NPI 1174622682, CMS profile ID 53553, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174622682?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $2,008.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $19.6405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848410099 CMS
AbbVie Inc. $15.8004/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338151 CMS
Lilly USA, LLC $19.2104/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819078541 CMS
Novo Nordisk Inc $11.0904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811083365 CMS
SANOFI-AVENTIS U.S. LLC $17.6704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843571833 CMS
AbbVie Inc. $15.4804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338149 CMS
AstraZeneca Pharmaceuticals LP $18.5804/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829410655 CMS
Lilly USA, LLC $14.8904/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819078537 CMS
Janssen Pharmaceuticals, Inc $17.6104/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956599 CMS
Lilly USA, LLC $15.0604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819171567 CMS
Novo Nordisk Inc $16.4904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811545749 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.0703/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763439858 CMS
AbbVie Inc. $6.4503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338147 CMS
Eisai Inc. $19.6403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817871125 CMS
Biogen, Inc. $19.3903/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827767769 CMS
AstraZeneca Pharmaceuticals LP $18.1403/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829272723 CMS
Lilly USA, LLC $17.8103/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819094345 CMS
Merck Sharp & Dohme Corporation $19.1003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848410033 CMS
Novartis Pharmaceuticals Corporation $21.4303/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812653773 CMS
GlaxoSmithKline, LLC. $15.3803/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802491973 CMS
AbbVie Inc. $18.5803/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338145 CMS
ARBOR PHARMACEUTICALS, INC. $13.2003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830938153 CMS
Novo Nordisk Inc $19.2403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811754595 CMS
AbbVie Inc. $8.1202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338143 CMS
Lilly USA, LLC $14.8902/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819094341 CMS
PFIZER INC. $20.1202/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833541325 CMS
Janssen Pharmaceuticals, Inc $16.6502/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787956605 CMS
Eisai Inc. $19.4202/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817849313 CMS
GlaxoSmithKline, LLC. $18.0202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802642145 CMS
Biogen, Inc. $22.6402/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827767767 CMS
AstraZeneca Pharmaceuticals LP $20.9202/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829366781 CMS
AstraZeneca Pharmaceuticals LP $20.6801/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830138801 CMS
SANOFI-AVENTIS U.S. LLC $16.5601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843571795 CMS
AbbVie Inc. $4.2501/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338141 CMS
Eisai Inc. $19.1701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817814051 CMS
ARBOR PHARMACEUTICALS, INC. $14.9001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830938123 CMS
Eisai Inc. $18.4101/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817824789 CMS
Lilly USA, LLC $14.9901/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819175359 CMS
AbbVie Inc. $14.3101/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338139 CMS
AbbVie Inc. $4.5501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338137 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.1701/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763439860 CMS
AbbVie Inc. $16.8801/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794338135 CMS
AstraZeneca Pharmaceuticals LP $42.1901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829587311 CMS
Lilly USA, LLC $14.9501/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819168577 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,710.13 77
PY2020 $1,502.72 74
PY2021 $2,008.58 94
PY2022 $1,548.12 58
PY2023 $1,106.59 56
PY2024 $1,791.24 51
PY2025 $1,266.59 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $27,660.00 64
PY2022 Recipient $750.00 1
PY2022 Principal investigator $645,969.60 16
PY2021 Principal investigator $44,285.60 9
PY2020 Recipient $12,682.37 15
PY2020 Principal investigator $259,772.27 26
PY2019 Principal investigator $458,432.13 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,250.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,000.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $850.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,825.00 09/13/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 09/06/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 09/06/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 09/06/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127471
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 08/15/2023 Non-covered Recipient Entity
Premier Research Association,inc
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1035952775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Premier Research Assoiciate, Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069379
Principal investigator 1 Genentech, Inc. $473.40 05/23/2023 Non-covered Recipient Entity
PREMIER RESEARCH ASSOCIATE INC
Phase II AntiFGFR 1 in NASH No dispute reported 06/30/2026 1040426981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997069347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 03/09/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068244
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 02/28/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068281
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 02/05/2023 Non-covered Recipient Entity
Premier Research Associate,Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997068299